News

PharmaLink Inc. and Recall Results, Inc. Announce Strategic Partnership to Enhance Drug Safety and Recall EfficiencyPharmaLink Inc. and Recall Results, Inc. Announce Strategic Partnership to Enhance Drug Safety and Recall Efficiency

PharmaLink Inc. and Recall Results, Inc. Announce Strategic Partnership to Enhance Drug Safety and Recall Efficiency

LARGO, FL / ACCESSWIRE / April 26, 2024 / PharmaLink Inc., a national leader in pharmaceutical reverse distribution, and Recall…

1 year ago
HCA Healthcare Reports First Quarter 2024 ResultsHCA Healthcare Reports First Quarter 2024 Results

HCA Healthcare Reports First Quarter 2024 Results

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the first quarter ended March 31,…

1 year ago
CompendiRx Unveils Innovative Approach to Long COVID: Empowering Patients WorldwideCompendiRx Unveils Innovative Approach to Long COVID: Empowering Patients Worldwide

CompendiRx Unveils Innovative Approach to Long COVID: Empowering Patients Worldwide

NASHVILLE, TN / ACCESSWIRE / April 26, 2024 / The latest data from the US Census Bureau reflects alarming statistics…

1 year ago
Senzime Signs its First Group Purchasing Organization (GPO) Contract with Major US Hospital System as Sole Source SupplierSenzime Signs its First Group Purchasing Organization (GPO) Contract with Major US Hospital System as Sole Source Supplier

Senzime Signs its First Group Purchasing Organization (GPO) Contract with Major US Hospital System as Sole Source Supplier

UPPSALA, SWEDEN / ACCESSWIRE / April 26, 2024 / Senzime (STO:SEZI)(OTCQX:SNZZF) has secured a three-year GPO contract with one of…

1 year ago
Curiteva Announces David Schmidt as Chief Commercial OfficerCuriteva Announces David Schmidt as Chief Commercial Officer

Curiteva Announces David Schmidt as Chief Commercial Officer

HUNTSVILLE, AL / ACCESSWIRE / April 26, 2024 / Curiteva, a privately held manufacturing and technology company, announces the appointment…

1 year ago
Notice Of Annual General Meeting in PMD Device Solutions AB (PUBL)Notice Of Annual General Meeting in PMD Device Solutions AB (PUBL)

Notice Of Annual General Meeting in PMD Device Solutions AB (PUBL)

STOCKHOLM, SWEDEN / ACCESSWIRE / April 26, 2024 / PMD Device Solutions (FRA:8T0)(STO:PMDS) The shareholders of PMD Device Solutions AB…

1 year ago
Biotricity’s Path Towards Breakeven Accelerated by Latest Diagnostic Product, Biotres Pro, Garnering Rapid Interest from Existing and New CustomersBiotricity’s Path Towards Breakeven Accelerated by Latest Diagnostic Product, Biotres Pro, Garnering Rapid Interest from Existing and New Customers

Biotricity’s Path Towards Breakeven Accelerated by Latest Diagnostic Product, Biotres Pro, Garnering Rapid Interest from Existing and New Customers

REDWOOD CITY, CA / ACCESSWIRE / April 26, 2024 / Biotricity Inc. (NASDAQ:BTCY), a pioneering Technology-as-a-Service (TaaS) company dedicated to…

1 year ago
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell CarcinomaAllogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell…

1 year ago
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)

Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)

April 26, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready…

1 year ago